WO2001049246A3 - Sustained release tablet formulations comprising clarithromycin - Google Patents

Sustained release tablet formulations comprising clarithromycin Download PDF

Info

Publication number
WO2001049246A3
WO2001049246A3 PCT/TR2001/000002 TR0100002W WO0149246A3 WO 2001049246 A3 WO2001049246 A3 WO 2001049246A3 TR 0100002 W TR0100002 W TR 0100002W WO 0149246 A3 WO0149246 A3 WO 0149246A3
Authority
WO
WIPO (PCT)
Prior art keywords
clarithromycin
sustained release
release tablet
release
tablet formulations
Prior art date
Application number
PCT/TR2001/000002
Other languages
French (fr)
Other versions
WO2001049246A2 (en
Inventor
Levent Oener
Ahmet Toksoez
Original Assignee
Sanovel Lac Sanay Ve T Caret A
Levent Oener
Ahmet Toksoez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Lac Sanay Ve T Caret A, Levent Oener, Ahmet Toksoez filed Critical Sanovel Lac Sanay Ve T Caret A
Priority to AU36329/01A priority Critical patent/AU3632901A/en
Publication of WO2001049246A2 publication Critical patent/WO2001049246A2/en
Publication of WO2001049246A3 publication Critical patent/WO2001049246A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention covers the sustained release tablets containing hydroxypropylmethylcellulose as matrix material and clarithromycin as active ingredient. Clarithromycin is released from sustained release tablet with a rate expressed by the equation Mt/M =ktn. In this equation n is the exponent of the release kinetics and n value determines the type of release mechanism. When n value is between 0.89 to 1, release rate complies with zero-order kinetic and it is independent from time.
PCT/TR2001/000002 2000-01-05 2001-01-04 Sustained release tablet formulations comprising clarithromycin WO2001049246A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36329/01A AU3632901A (en) 2000-01-05 2001-01-04 Sustained release tablet formulations comprising clarithromycin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2000/00054A TR200000054A2 (en) 2000-01-05 2000-01-05 Sustained-release tablet formulations containing clarithromycin.
TR2000/00054 2000-01-05

Publications (2)

Publication Number Publication Date
WO2001049246A2 WO2001049246A2 (en) 2001-07-12
WO2001049246A3 true WO2001049246A3 (en) 2002-08-15

Family

ID=21622322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2001/000002 WO2001049246A2 (en) 2000-01-05 2001-01-04 Sustained release tablet formulations comprising clarithromycin

Country Status (3)

Country Link
AU (1) AU3632901A (en)
TR (1) TR200000054A2 (en)
WO (1) WO2001049246A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1285659T1 (en) * 2001-08-13 2008-02-29 Fond Salvatore Maugeri Clinica Use of clarithromycin compositions in the manufacture of a medicament for the treatment of arthritis deformans
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
EP1720524A2 (en) * 2004-02-26 2006-11-15 Ranbaxy Laboratories Limited Extended release tablets of clarithromycin
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967256A (en) * 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd Drug for common cold
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
WO2000048607A1 (en) * 1999-02-19 2000-08-24 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Directly compressible matrix for controlled release of single daily doses of clarithromycin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967256A (en) * 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd Drug for common cold
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
WO2000048607A1 (en) * 1999-02-19 2000-08-24 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Directly compressible matrix for controlled release of single daily doses of clarithromycin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9720, Derwent World Patents Index; AN 1997-221692, XP002176786, "Remedies for colds- comprise ibuprofen and/or acetaminophen and clarithromycin" *

Also Published As

Publication number Publication date
TR200000054A2 (en) 2001-08-21
WO2001049246A2 (en) 2001-07-12
AU3632901A (en) 2001-07-16

Similar Documents

Publication Publication Date Title
HK1046244A1 (en) Controlled release and taste masking oral pharmaceutical compositions.
CA2232450A1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
CA2199778A1 (en) Extended release formulation of venlafaxine
EP1135173A4 (en) A medicinal aerosol formulation
WO2000019985A3 (en) New sustained release oral formulations
CA2395231A1 (en) Hydrogel-driven layered drug dosage form
EP2033648A3 (en) Sustained release drug delivery system containing prodrugs
HUP0102206A2 (en) Delavirdine tablet formulation
WO2002045571A3 (en) Fast dissolving tablet
MXPA03008062A (en) Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent.
WO2007052125A3 (en) Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
WO2005020957A3 (en) Stepwise delivery of topiramate over prolonged period of time
NZ504460A (en) Sustained release formulations containing venlafaxine
MY127350A (en) Flash-melt oral dose formulations
WO2005007137A8 (en) Tablets containing ambroxol
WO2001049246A3 (en) Sustained release tablet formulations comprising clarithromycin
AU1244199A (en) Tablets to be crunched or sucked, comprising iron as active principle
FI963567A (en) The diclofenacs containing prolonged-release tablets
MY128759A (en) Oral controlled release formulations
AU3706999A (en) Controlled release tablet produced from linear water-insoluble polysaccharides
MXPA01008348A (en) Microcapsules for sustained release of drugs.
WO2003020265A3 (en) Compositions comprising pectin and ascorbic acid
AU2540499A (en) Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content
IL138771A0 (en) A compacted 2,2-dibromo-3-nitrilopropionamide
WO2002007672A3 (en) A medicinal aerosol formulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP